Sub Saharan Africa


At AstraZeneca, science is at the core of everything we do. But more than that, science is who we are.

In AstraZeneca Sub Saharan Africa every one of our employees makes a difference to patient lives every day. We are inspired by the things that seem impossible – being entrepreneurial, thinking big and working together to change the course of treatment and medicine. We believe in the potential of science to address the unmet needs of patients across Sub Saharan Africa and we are determined to make the right decisions that will transform their lives.

In 2009 AstraZeneca announced our expansion plans to grow our presence in Sub Saharan Africa through the roll-out of a strong investment and capacity building strategy, under the axiom ‘In Africa for Africa’. As part of a global science-led organisation Sub Saharan Africa is well placed to broaden the access to innovative medicines to more patients in Sub Saharan Africa, adopting a localised approach suited to the countries we operate in.

We want to be valued as a source of great medicines over the long term, by operating in a way that recognises the interconnection between business growth and the needs of communities. Our sustainability efforts are aligned to, and support the delivery of our business strategy through access to healthcare; building a great place to work, responsible research and ethical business practices. We work to consistent global standards of ethical sales and marketing practices in all our markets to realise our growth potential. 

We market medicines that are designed to improve the health and quality of life of patients, focusing on 3 main therapy areas: Respiratory; Cardiovascular and Metabolic diseases (CVMD); and Oncology. 

CONTACT US

Physical address: 
Building 2
Northdowns Office Park
17 Georgian Crescent West
Bryanston

Postal address:
Private Bag X23
Bryanston
2021
South Africa

Telephone:
+27 (0)11 797-6000


Sub Saharan Africa focus areas

Sub Saharan Africa Cluster

Our Sub Saharan Africa cluster includes regional offices as well as country offices. Our regional and country offices serve as a hub of communication between our office-based staff and more than half the company's employees that are directly involved in the promotion of our medicines to healthcare professionals in Sub Saharan Africa.   

Our Sub Saharan Africa cluster includes the following countries:

Angola, Botswana, Ethiopia, Ghana, Kenya, Lesotho, Madagascar, Mauritius, Mozambique, Namibia, Nigeria, Rwanda, Swaziland, Tanzania, Uganda, Zambia, Zimbabwe


East Africa Region

AstraZeneca East Africa Region is represented in Ethiopia, Kenya, Rwanda, Tanzania and Uganda. 

The registration of AstraZeneca Kenya as a legal entity in 2016 reinforces our long-term growth ambition and commitment in the East Africa Region and the establishment of a regional distribution hub in East Africa in 2015 enables us to bring our products closer to our patients.

AstraZeneca’s Healthy Heart Africa (HHA) is our global signature programme committed to tackling hypertension and the increasing burden of cardiovascular disease (CVD) across Africa.  The innovative programme was launched in Kenya October 2014, in collaboration with the Kenyan Ministry of Health and a group of well-respected implementing partners.  In early 2016 we took our learnings to Ethiopia where we announced Healthy Heart Africa, in partnership with the Ethiopian Federal Ministry of Health.

More information about Healthy Heart Africa can be found on our global website.

Southern Africa Region

AstraZeneca Southern Africa Region operates in Angola, Botswana, Lesotho, Madagascar, Mauritius, Mozambique, Namibia, Swaziland, Zambia and Zimbabwe, with geographic coverage for Cape Verde, Guinea and Malawi. The regional office for Southern Africa is based in, Johannesburg South Africa and offers marketing and sales support to the other countries. 

Mauritius and Angola are important countries for the AstraZeneca business and in many instances the SSA pilot countries for launches due to its fast regulatory approval timeframe. Our Southern Africa countries have been able to positively impact their respective communities by introducing AstraZeneca products and supporting scientific knowledge and education in the region.

In Angola and Mozambique we work extensively to bring some of the best Portuguese educational resources and key experts to the region to expand medical education programmes and knowledge sharing with local Health Care Professionals.

West Africa Region

In West Africa AstraZeneca is represented in Ghana and Nigeria, by a team of sales and marketing personnel and medical science liaisons, that work to add value to healthcare not only through delivery of our innovative medicines, but also by prioritising the continuous medical education of healthcare professionals.

AstraZeneca West Africa has over the years contributed to advancement of patient-centric care though its collaboration with various health care organizations and fraternities.

In Ghana, AstraZeneca has launched Phakamisa (Enidaso). The programme provides a holistic approach to breast cancer care, spanning awareness creation, training of healthcare personnel and improving access to medicines.



Our investment in continuous medical education

 
  • We have a strong scientific team of qualified Medical Doctors providing key scientific support, across our key therapeutic areas, to our AstraZeneca teams and our customers.
  • We collaborate with different medical societies to increase awareness of global management guidelines. We continually explore additional areas for collaboration with medical and pharma societies, with the aim of supporting the education of Health Care Professionals (HCPs).
  • We have worked extensively to bring some of the best educational resources and key experts to Sub Saharan Africa to expand scientific education programmes and knowledge sharing amongst HCPs.
  • AstraZeneca Sub Saharan Africa utilizes live WebEx platforms to host international speakers, bringing international knowledge to the region and combining this with local expertise.
  • The Greatminds platform in Sub Saharan Africa enables our Medical Representatives to deliver unique rep hosted events, providing doctors access to current, relevant content with international and local speakers. An interactive learning experience utilizing technology that offers a solution that best suits doctors’ needs and time.

 


Supporting our patients and communities

At AstraZeneca we work together across global boundaries to make an impact and find answers to challenges.

Our commitment to improve health outcomes for Sub Saharan Africa patients extends far beyond our medicines. We offer programmes that advance patient health and access along the care continuum and provide reliable support networks.

Phakamisa /Enidaso

Our Phakamisa Oncology programme in Ghana and Kenya brings together different organisations to help raise awareness of breast cancer and prostate cancer; strengthen healthcare capabilities; and improve access to treatment and support networks. The vision of the program is to reduce the burden of breast and prostate cancer on the national health system by the promotion of primary prevention, early detection and access to affordable medicines.

Global projects in our cluster

Healthy Heart Africa is an innovative programme committed to tackling hypertension and the increasing burden of cardiovascular disease (CVD) across Africa.  Healthy Heart Africa aspires to reach 10 million hypertensive patients across Sub-Saharan Africa by 2025, supporting the World Health Organisation’s global hypertension target (25% reduction by 2025). The programme was launched in October 2014 in collaboration with the Kenyan Ministry of Health and a group of well-respected implementing partners.  We have developed strong relationships with local health partners, governments and Ministries of Health in the region; with Memorandums of Understanding entered into with the Ministries of Health in Kenya and in Ethiopia.  In early 2016 we took our learnings to Ethiopia where we announced HHA, in partnership with the Ethiopian Federal Ministry of Health.

Healthy heart Africa has now embarked on an innovative partnership with PEPFAR to tackle the burden of HIV and hypertension in Africa.  The partnership will jointly invest up to $10 million over 5 years to integrate hypertension services into existing HIV platforms across Africa to improve HIV and hypertension care. More information about the programme can be found here.

Young Health Programme has a unique focus on young people and primary prevention of the most common non-communicable diseases (NCDs). Working in partnership with global and local organisations, Young Health Programme works to positively impact the health of adolescents through research, evidence generation, advocacy for change and on-the-ground programmes. The global AstraZeneca sponsored programme was launched in Kenya in 2016 and aims to contribute to improved health and gender equality of 82 000 young people, aged 10-24, in Kibera, Kenya, over 5 years. More information about the Young Health Programme can be found here.



Working at AstraZeneca

At AstraZeneca South Africa we are guided in our work by a strong set of values, and we’re resetting expectations of what a bio-pharmaceutical company can be. By truly following the science, we pioneer new methods, new thinking and bring unexpected teams together.

From medical science to sales & marketing, we’re on a mission to turn ideas into life-changing medicines that transform lives.

If you’re inspired by the possibilities of science to make a difference and ready to discover what you can do – join us.



Good governance

Good governance is crucial to ensuring we are well managed and can deliver our strategic priorities. Our Code of Conduct sets out the ethical standards we expect of everyone who works at AstraZeneca and, along with our global policies, how these are to be translated into consistent actions worldwide.

Patient safety and adverse event reporting

The safety of patients who take our medicines is of fundamental importance to AstraZeneca. We continuously work to identify and minimise the risks and maximise the benefits of each of our medicines. A vital aspect of our commitment to patient safety is making sure that accurate up-to-date information is provided to support effective use of our medicines.

If you would like to report an adverse event for an AstraZeneca product please contact AstraZeneca Safety:   

Phone: +27 11 797 6243

Fax: +27 872 38 7011

Email: PatientSafetySSA@astrazeneca.com

Online: http://aereporting.astrazeneca.com